Lantern Pharma Stock Discussion

$Lantern Pharma (LTRN.US)$
Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality
Lantern Pharma and its subsidiary Starlight Therapeutics presented new preclinical data and Phase 1b trial design for LP-184 (STAR-001) in glioblastoma at SNO 2024.
The data shows LP-184 combined with spironolactone increases GBM cell sensitivity up to 6-fold thro...

$Lantern Pharma (LTRN.US)$ Reuters· 2 mins ago
Lantern Pharma & Starlight Therapeutics Present LP-184 (Star-001) Phase 1B Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (Sno) 2024 Highlighting Novel Synthetic Lethality

$Lantern Pharma (LTRN.US)$ Lantern Pharma Announces First Patient Dosed in Japan for the Expansion Cohort in the Phase 2 Harmonic™ Clinical Trial of LP-300 in Never-Smoker Nsclc Patients

$China Pharma (CPHI.US)$ $Bright Minds Biosciences (DRUG.US)$ $Lantern Pharma (LTRN.US)$ $Cytosorbents (CTSO.US)$ $Intensity Therapeutics (INTS.US)$ $Multi Ways (MWG.US)$ $Salarius Pharmaceuticals (SLRX.US)$ $X3 Holdings (XTKG.US)$ $Protagenic Therapeutics (PTIX.US)$ $GRI Bio (GRI.US)$ $Paranovus Entertainment Technology (PAVS.US)$ $VSee Health (VSEE.US)$
📊⚡️📊

$Lantern Pharma (LTRN.US)$ Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA
6 MINUTES AGO, 9:07 AM EDT
VIA BUSINESSWIRE

$Lantern Pharma (LTRN.US)$
Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children's Cancers
• Lantern Pharma was granted the rare pediatric disease designation (RPDD) for drug-candidate, LP-184, in three cancer indications: Malignant Rhabdoid Tumors, Rhabdomyosarcoma, and Hepatoblastoma.
• This brings the total number of RPDDs for LP-184 to 4, including one previously granted for ATRT (Atypical Teratoid Rhabdoid Tumors)....

$Lantern Pharma (LTRN.US)$ This possible play is purely chart driven! Thats the reason im sharing. So those that asked. Here is a example of some of what i look for. This is what brought my attention here🤔🤫

$Lantern Pharma (LTRN.US)$
Lantern Pharma Highlights Promising Preclinical Results of LP-184’s Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024
Lantern Pharma (NASDAQ: LTRN) announced promising preclinical results for LP-184, demonstrating synergy with checkpoint inhibitors and the ability to resensitize tumors non-responsive to Anti-PD1 therapies. Key findings include:
1. LP-18...